Emerging importance of alpha-adrenergic coronary vasoconstriction in acute coronary syndromes and its genetic background  by Heusch, Gerd
EDITORIAL COMMENT
Emerging Importance of Alpha-
Adrenergic Coronary
Vasoconstriction in Acute
Coronary Syndromes and its
Genetic Background*
Gerd Heusch, MD, FESC, FACC, FAHA, FISHR
Essen, Germany
As compared to the beta-adrenoceptor–mediated effects of
sympathetic activation, alpha-adrenoceptor–mediated ef-
fects on coronary blood flow have long received little
attention. This was largely due to the fact that, in animal
experiments under physiologic circumstances, there is very
little alpha-adrenergic coronary vasomotor tone at rest, and
the increase in coronary blood flow during sympathetic
activation is only somewhat blunted. More recent experi-
mental studies, however, clearly demonstrated that, when
the coronary circulation is compromised by hypercholester-
olemia (1), endothelial dysfunction (2), exhaustion of auto-
regulation (3), or severe coronary stenoses (4,5), alpha-
adrenergic vasoconstriction is unrestrained and powerful
enough to reduce coronary blood flow and induce myocar-
dial ischemia (6). Both, alpha1- and alpha2-adrenoceptors
mediate such coronary vasoconstriction, with alpha2-
adrenoceptors more predominant in the microcirculation
(3,7).
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Over the last decade, various studies using quantitative
coronary angiography, Doppler flow probes, and positron
emission tomography have demonstrated the importance of
alpha-adrenergic coronary vasoconstriction in humans (8).
As in animal experiments, studies in humans under physi-
ologic conditions show there is no limitation of resting
coronary blood flow by alpha-adrenergic coronary vasocon-
striction, but there is a limitation of coronary reserve (9).
However, again as in the animal experiments, alpha-
adrenergic coronary vasoconstriction is enhanced in patients
with endothelial dysfunction and atherosclerosis (10–12).
In patients with established coronary artery disease (CAD),
both selective alpha1- and alpha2-adrenoceptor activation
induce augmented coronary vasoconstriction, and alpha2-
adrenergic vasoconstriction is then powerful enough to
induce net lactate production and electrocardiographic signs
of ischemia (11). Notably, reflex alpha-adrenergic coronary
vasoconstriction is also elicited during coronary interven-
tions (13,14), and this contributes to postinterventional
contractile dysfunction (15,16).
Very recently, a genetic determination of alpha-
adrenergic coronary vasoconstriction has emerged (17). A
polymorphism in the gene encoding for the G3 subunit of
pertussis-sensitive G proteins, which is associated with
alternative splicing and enhanced signal transduction (18),
induces a pronounced supersensitivity to alpha2-adrenergic
coronary vasoconstriction in the 825T-allele carriers, which
adds to the augmentation of alpha-adrenergic coronary
vasoconstriction in the presence of atherosclerosis per se
(19).
It is against this background that the current study by
Snapir et al. (20) in this issue of the Journal provides
additional evidence for the importance of alpha2-adrenergic
coronary vasoconstriction and its genetic determination. A
deletion/insertion polymorphism in the alpha2B-
adrenoceptor (21) has previously been shown by these
investigators to be a novel genetic risk factor for CAD,
insofar as individuals with the deletion/deletion genotype
had an increased risk of acute myocardial infarction in a
population-based prospective study (22). The study by
Snapir et al. (20) extends the prior study and points to the
importance of alpha2-adrenergic coronary vasoconstriction
in the causal pathogenesis of myocardial infarction and also
sudden cardiac death in a well-characterized, unselected
cohort of Caucasian men who had suffered out-of-hospital
death. Of note, the classical risk factors for CAD in the
deletion/deletion genotype were no different from those in
the insertion/deletion and insertion/insertion genotype.
In addition, no difference was observed in the extent of
coronary atherosclerosis at autopsy. Finally, there was no
evidence for coronary thrombosis at autopsy, further sup-
porting the importance of enhanced alpha2-adrenergic cor-
onary vasoconstriction as the underlying mechanism of
acute myocardial infarction and sudden cardiac death.
The major limitation of the present study (20), as with all
other association studies, is its purely descriptive nature and
the lack of definition of a functional phenotype (17). Of
note, such functional phenotype was defined for the G3
subunit polymorphism (19), and this clearly needs to be
done for the alpha2B-polymorphism in the future, too. It
is also tempting to speculate about a potentially additive
genetic risk conferred by a combination of the 825T-
allele of the G3 subunit and the deletion/deletion
genotype of the alpha2B-adrenoceptor in further enhanc-
ing alpha2-adrenoceptor–mediated signal transduction,
resulting coronary microvascular constriction and ulti-
mately inducing acute myocardial infarction and sudden
cardiac death. Future studies will most certainly resolve
this question.
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